CUE BIOPHARMA, INC.

Profile

Company Names

CUE BIOPHARMA, INC.
IMAGEN BIOPHARMA, INC.

Addresses

40 GUEST STREET, BOSTON, MA 02458

675 W. KENDALL STREET, CAMBRIDGE, MA 02142

401 WILSHIRE BLVD., SUITE 1020, SANTA MONICA, CA 90401

Phone Numbers

617-949-2680
310-526-5000

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2014

State Incorporated:

DELAWARE

Total Amount Raised:

$76,414,885.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2026-05-04 
$29,999,992.00 
$29,999,992.00 
$0.00 
 
3
2022-11-16 
$29,999,993.00 
$29,999,993.00 
$0.00 
Equity 
2
2016-12-22 
$16,414,900.00 
$16,414,900.00 
$0.00 
Equity 
1
2015-06-15 
$0.00 
$1,000,000.00 
$1,000,000.00 
 
People
First Name
Middle Name
Last Name
Titles
Related Companies
STEVEN 
 
ALMO 
EXECUTIVE OFFICER
IMAGEN BIOPHARMA, INC.
DANIEL 
 
BAKER 
EXECUTIVE OFFICER
PLUMCHOICE INC   |  CALPACIFIC EQUITY FUND I LLC   |  CALPACIFIC EQUITY FUND II LLC   |  REDLOCK CAPITAL FUND I LP   |  CUE BIOPHARMA, INC.
JILL 
M. 
BROADFOOT 
DIRECTOR
CUE BIOPHARMA, INC.
RODOLFO 
 
CHAPARRO 
EXECUTIVE OFFICER
IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  CROSSLINK THERAPEUTICS INC.
ANTHONY 
 
DIGIANDOMENICO 
DIRECTOR
XELR8 HOLDINGS, INC.   |  ENDRA, INC.   |  IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  PROVENTION BIO, INC.   |  ENDRA LIFE SCIENCES INC.   |  MDB CAPITAL HOLDINGS, LLC   |  INVIZYNE TECHNOLOGIES INC
FREDERICK 
 
DRISCOLL 
DIRECTOR
CUE BIOPHARMA, INC.
AARON 
 
FLETCHER 
DIRECTOR
LUNG THERAPEUTICS, INC.   |  COGNITION THERAPEUTICS INC   |  BIOS LTI SPV II, LP   |  TFF PHARMACEUTICALS, INC.   |  ABILITECH MEDICAL, INC.   |  XY GAMING, INC.   |  CUE BIOPHARMA, INC.   |  BIOS SPECIAL OPPORTUNITY FUND II, LP   |  ACTUATE THERAPEUTICS, INC.   |  ONL THERAPEUTICS, INC.
PAMELA 
D. 
GARZONE 
DIRECTOR
CUE BIOPHARMA, INC.
CAMERON 
 
GRAY 
EXECUTIVE OFFICER, DIRECTOR
IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  PROVENTION BIO, INC.   |  VIEWPOINT MOLECULAR TARGETING, INC.   |  ITOLERANCE, INC.
TAMAR 
 
HOWSON 
DIRECTOR
IMMUNIC, INC.   |  CUE BIOPHARMA, INC.
PETER 
 
KIENER 
DIRECTOR
ZYNGENIA, INC.   |  RESOLVE THERAPEUTICS LLC   |  CUE BIOPHARMA, INC.   |  TETRAGENETICS INC   |  GT BIOPHARMA, INC.   |  WUGEN, INC.
PETER 
A. 
KIENER 
DIRECTOR
ZYNGENIA, INC.   |  ITOLERANCE, INC.   |  CUE BIOPHARMA, INC.
SHAO-LEE 
 
LIN 
EXECUTIVE OFFICER, DIRECTOR
CUE BIOPHARMA, INC.
CHRISTOPHER 
 
MARLETT 
DIRECTOR
ELECTROBLATE, INC.   |  IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  THEMAVEN, INC.   |  MDB CAPITAL HOLDINGS, LLC   |  INVIZYNE TECHNOLOGIES INC
STEVEN 
 
MCKNIGHT 
DIRECTOR
CUE BIOPHARMA, INC.
KERRI-ANN 
 
MILLAR 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.   |  SYNCROMUNE, INC.
FRANK 
 
MORICH 
DIRECTOR
CUE BIOPHARMA, INC.   |  PERSPECTIVE THERAPEUTICS, INC.
PATRICIA 
 
NASSHORN 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.
DANIEL 
 
PASSERI 
EXECUTIVE OFFICER, DIRECTOR
CUE BIOPHARMA, INC.
DANIEL 
R. 
PASSERI 
EXECUTIVE OFFICER, DIRECTOR
CURIS INC   |  CUE BIOPHARMA, INC.
KEN 
 
PIENTA 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.
COLIN 
 
SANDERCOCK 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.
COLIN 
G. 
SANDERCOCK 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.
PASHA 
 
SARRAF 
DIRECTOR
CUE BIOPHARMA, INC.
GARY 
 
SCHUMAN 
EXECUTIVE OFFICER, DIRECTOR
IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  THEMAVEN, INC.
RONALD 
 
SEIDEL III 
EXECUTIVE OFFICER
IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.
BARRY 
 
SIMON 
DIRECTOR
COBRA STYLET L.L.C.   |  CONKWEST, INC.   |  CUE BIOPHARMA, INC.   |  VIRACTA THERAPEUTICS, INC.   |  IMMUNITYBIO, INC.   |  CADEN FLV LLC   |  CADEN LONG EQUITY FUND, L.P.   |  CADEN OPPORTUNITY FUND, L.P.
ANISH 
 
SURI 
EXECUTIVE OFFICER
CUE BIOPHARMA, INC.
PATRICK 
 
VERHEYEN 
DIRECTOR
CUE BIOPHARMA, INC.
AMY 
 
WANG 
EXECUTIVE OFFICER, DIRECTOR
LIQUID GENOMICS, INC.   |  ELECTROBLATE, INC.   |  IMAGEN BIOPHARMA, INC.   |  CUE BIOPHARMA, INC.   |  ENSPIRE BIO, INC.   |  CAPACITY BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2026-05-14
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2026-05-04 
2022-11-21
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2022-11-16 
2016-12-30
D/A
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2016-12-22 
2016-12-22
D
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2016-12-22 
2015-06-19
D
Link
BIOTECHNOLOGY 
 
NO REVENUES 
 
2015-06-15 
2015-06-19
D
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2015-06-15 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
NEWBRIDGE SECURITIES CORPORATION
104065
PIPER SANDLER + CO.
NONE
PIPER SANDLER + CO.
665
NONE
NONE
PUBLIC VENTURES, LLC
42677
NONE
NONE
MDB CAPITAL GROUP, LLC
42677
NONE
NONE
MDB CAPITAL GROUP, LLC
42677